Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityWAC / Walter Investment Management Corp. (93317W102)
CEO & PresidentRenzi Anthony N.
IndustryMortgage Bankers and Loan Correspondents
Institutional Owners7
Institutional Shares10,415,424 - 225.12%
Institutional Value$ 43,175,000 USD
Related DHCP / Ditech Holding Corporation
DHCP.WSA / Ditech Holding Corporation Series A Warrants
DHCP.WSB / Ditech Holding Corporation Series B Warrants
93317WAA0 / Walter Investment Management Corp. Bond

Institutional Stock Ownership and Shareholders()

WAC / Walter Investment Management Corp. Institutional Ownership

Walter Investment Management Corp. (NYSE:WAC) has 7 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 10,415,424 shares. Largest shareholders include Baker Street Capital Management, LLC, BlackRock Institutional Trust Company, N.A., BlackRock Fund Advisors, BlackRock Investment Management, LLC, Pacific Alternative Asset Management Company, Llc, BlackRock Group LTD, and BlackRock Advisors LLC.
Walter Investment Management Corp. (NYSE:WAC) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/wac"><img src="https://images.fintel.io/us-wac-so.png" alt="WAC / Walter Investment Management Corp. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-07 13F-HR AMERICAN INTERNATIONAL GROUP INC 413 0 -100.00 0 0
2018-05-15 13F-HR HIGHLAND CAPITAL MANAGEMENT LP 550,000 0 -100.00 464 0 -100.00
2018-05-12 13F-HR First Pacific Advisors, LLC 162,995 0 -100.00 137 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 14,841 0 -100.00 13 0 -100.00
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 18,768 0 -100.00 16 0 -100.00
2018-05-11 13F-HR MACQUARIE GROUP LTD 40,200 0 -100.00 34 0 -100.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 305,100 0 -100.00 257 0 -100.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 54,929 0 -100.00 46 0 -100.00
2018-05-15 13F-HR Invesco Ltd. 288,463 0 -100.00 243 0 -100.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 165 0 -100.00 0 0
2017-02-10 13F-HR BlackRock Fund Advisors 563,335 622,267 10.46 2,287 2,956 29.25
2018-05-11 13F-HR Cutler Group LP 23,200 0 -100.00 19 0 -100.00
2018-05-15 13F-HR VANGUARD GROUP INC 514,261 0 -100.00 433 0 -100.00
2018-05-15 13F-HR UBS Group AG 162,068 0 -100.00 136 0 -100.00
2018-05-15 13F-HR Advisor Group, Inc. 10 0 -100.00 0 0
2018-05-15 13F-HR STATE STREET CORP 24,927 0 -100.00 21 0 -100.00
2018-05-14 13F-HR Virtu Financial LLC 35,979 0 -100.00 30 0 -100.00
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 37 0 -100.00 0 0
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 919,203 896,299 -2.49 3,732 4,257 14.07
2018-05-09 13F-HR FEDERATED INVESTORS INC /PA/ 23,680 0 -100.00 20 0 -100.00
2018-05-09 13F-HR BlackRock Inc. 35,795 0 -100.00 30 0 -100.00
2018-05-15 13F-HR PANAGORA ASSET MANAGEMENT INC 894 0 -100.00 1 0 -100.00
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 2,439 0 -100.00 2 0 -100.00
2018-05-08 13F-HR Phoenix Investment Adviser LLC 100,000 0 -100.00 84 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 81 0 -100.00 0 0
2018-04-27 13F-HR TELEMUS CAPITAL, LLC 198,365 0 -100.00 167 0 -100.00
2018-05-15 13F-HR Weiss Multi-Strategy Advisers LLC 735,000 0 -100.00 619 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 85,079 83,869 -1.42 345 398 15.36
2018-05-08 13F-HR Advisornet Financial, Inc 2,512 0 -100.00 2 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC Put 92,000 0 -100.00 78 0 -100.00
2017-08-11 13F-HR PACIFIC ALTERNATIVE ASSET MANAGEMENT COMPANY, LLC 53,500 81,900 53.08 58 78 34.48
2018-05-15 13F-HR Birch Run Capital Advisors, LP 7,474,587 0 -100.00 6,300 0 -100.00
2016-11-14 13F-HR Baker Street Capital Management, LLC 8,677,524 8,677,524 0.00 23,949 35,231 47.11
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 11,064 0 -100.00 9 0 -100.00
2018-05-09 13F-HR NORTHERN TRUST CORP 30,197 0 -100.00 25 0 -100.00
2017-02-10 13F-HR BlackRock Group LTD 40,984 41,992 2.46 166 200 20.48
2018-05-15 13F-HR Centerbridge Partners, L.P. 1,096,787 0 -100.00 924 0 -100.00
2018-05-11 13F-HR Cutler Group LP Put 600 0 -100.00 1 0 -100.00
2018-05-15 13F-HR ARROWGRASS CAPITAL PARTNERS (US) LP 971,404 0 -100.00 819 0 -100.00
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 65,778 0 -100.00 55 0 -100.00
2018-05-15 13F-HR Ameritas Investment Partners, Inc. 3,297 0 -100.00 8 0 -100.00
2017-02-10 13F-HR BlackRock Advisors LLC 11,364 11,573 1.84 46 55 19.57

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Ditech Holding Corporation (DHCP) CEO Tom Marano on Q1 2018 Results - Earnings Call Transcript

2018-06-06 seekingalpha
Ditech Holding Corporation (NYSE:DHCP) Q1 2018 Results Earnings Conference Call June 6, 2018 9:00 AM ET (20-4)

CUSIP: 93317W102